Almac Doubles Global 2-8°C Cold Room Capacity In Response To Increasing Biologics Demand

Dedicated temperature and humidity controlled labelling suites go live in USA and Europe as business from biosimilars and biologics clinical studies expands

Almac recently announced a significant investment to more than double the existing capacity of their 2-8°C clinical supply labelling cold room facilities in the Group’s European and USA based facilities.

Additional dedicated temperature and humidity controlled labelling suites have been installed and are now live at Almac’s headquarter sites situated in Craigavon (UK), Souderton (PA) and Durham (NC) increasing their capacity to label temperature sensitive investigational products. This expansion represents the latest development in the company’s investment initiatives designed to meet growing client demand for specific services including a significant upsurge in clinical studies for biosimilar and biological investigational products.

The expansion of Almac’s cold room facilities adds significant capacity or clients requiring the development of valuable biologically sensitive investigational products, whilst complementing the company’s existing clinical supply chain management services.

Commenting on this latest expansion, Robert Dunlop, Managing Director of Almac’s Clinical Services Business Unit remarked: "We have witnessed significant growth in the biologics market in the past 12 months and this latest investment reflects both our on-going commitment to meeting the demands of the clinical trial market, as well as our ability to expand and adapt successfully to key developments within the pharmaceutical and biotech industries. These are exciting times for Almac as we continue to increase our range of services to deliver world class solutions to our global client base."

The cold room facilities expansion follows on from other recently announced investments including £54M spent on the company’s pharmaceutical development and clinical services operations. This is in addition to the establishment of regional operations centres through strategic investments in Singapore and Japan geared towards meeting increasing customer demand in the Asia Pacific region. 

About Almac Group
‘Partnering to Advance Human Health’

The Almac Group is an established contract development and manufacturing organisation that provides an extensive range of integrated services to over 600 companies globally within the pharmaceutical and biotech sectors. The services range from R&D, biomarker discovery and development, API manufacture, formulation development, clinical trial supply, IXRS® technology (IVRS/IWRS) through to commercial-scale manufacture.

The international company is a privately owned organisation that has organically grown over 30 years and now employs in excess of 3,500 highly skilled personnel. Almac is headquartered in Craigavon, Northern Ireland with operations across the US (Pennsylvania, North Carolina and California) and in Asia (Singapore and Tokyo). For more information, visit www.almacgroup.com.